Develops targeted drug candidates to treat breast and other cancers in patients.
10-K for FY2025, filed Mar 16, 2026Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation…View ↗
Our lead product candidate, palazestrant (formerly known as OP-1250), is a novel, orally-available small molecule with dual activity as…View ↗
Our second product candidate in clinical development, called OP-3136, is a novel, orally-available small molecule that potently and…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 16, 2026
10-Q for Q3 FY2026, filed Nov 10, 2026
−$73.6MView ↗
8-K, filed Aug 13, 2026
On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial…View ↗
Scope beyond breast cancer
The earlier report framed the company around therapies for women’s cancers; the latest also describes work on candidates for other cancers, alongside its breast cancer programs.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted…View ↗
Loading...